ECM
ALLO icon

ExodusPoint Capital Management’s Allogene Therapeutics ALLO Stock Holding History

ExodusPoint Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157K Buy
+64,313
New +$129K ﹤0.01% 1405
2024
Q4 		– Sell
-1,634,838
Closed -$4.58M – 1471
2024
Q3 		$4.58M Buy
1,634,838
+1,343,724
+462% +$3.58M 0.03% 456
2024
Q2 		$678K Buy
291,114
+128,091
+79% +$378K ﹤0.01% 1139
2024
Q1 		$729K Sell
163,023
-299,804
-65% -$1.25M 0.01% 1042
2023
Q4 		$1.49M Buy
462,827
+352,837
+321% +$1M 0.01% 670
2023
Q3 		$349K Sell
109,990
-317,762
-74% -$1.39M ﹤0.01% 1369
2023
Q2 		$2.13M Sell
427,752
-247,527
-37% -$1.34M 0.02% 783
2023
Q1 		$3.34M Sell
675,279
-483,422
-42% -$3.1M 0.03% 672
2022
Q4 		$7.29M Buy
1,158,701
+935,460
+419% +$8.66M 0.11% 253
2022
Q3 		$2.41M Buy
223,241
+192,738
+632% +$2.62M 0.03% 708
2022
Q2 		$348K Sell
30,503
-18,857
-38% -$167K ﹤0.01% 1479
2022
Q1 		$450K Sell
49,360
-84,940
-63% -$885K 0.01% 1594
2021
Q4 		$2M Buy
+134,300
New +$2.37M 0.02% 760
2021
Q3 		– Sell
-12,475
Closed -$325K – 2062
2021
Q2 		$325K Buy
12,475
+1,941
+18% +$55.4K ﹤0.01% 1688
2021
Q1 		$372K Buy
+10,534
New +$355K 0.01% 1536

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ExodusPoint Capital Management's ALLO Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Allogene Therapeutics (ALLO) in Q1 2026: 64,313 shares worth $157K. The stake represents ﹤0.01% of the portfolio and ranks #1405 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in ALLO as recently as Q3 2024.

ExodusPoint Capital Management first reported a position in ALLO in Q1 2021 and has held it in 15 quarters since. The position peaked at $7.29M in Q4 2022. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • ExodusPoint Capital Management held 64,313 shares of Allogene Therapeutics worth $157K as of Q1 2026.
  • Allogene Therapeutics was a new ExodusPoint Capital Management position in Q1 2026.
  • Allogene Therapeutics made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1405 holding.
  • ExodusPoint Capital Management first reported a position in Allogene Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • ExodusPoint Capital Management's Allogene Therapeutics position peaked at $7.29M in Q4 2022.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.